BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.
New AAN guidance examines how consumer wearable devices can support neurologic care, including epilepsy monitoring and sleep tracking — while cautioning that many of them are insufficiently validated.
Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atrial fibrillation. This incorporation represents a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results